

October 2, 2019

United States Nuclear Regulatory Commission Region III, Materials Licensing 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

RE: Amendment to NRC License No. 13-18881-01

**Memorial Hospital** 

Dear Madam or Sir:

We wish to amend our Materials License # 13-18881-01 to add Dr. Michael Hall, M.D. as an Authorized User for 10 CFR 35.1000, Yttrium-90 in SIR-spheres therapy delivery system. Dr. Hall is currently an Authorized User on our license for Yttrium-90 TheraSpheres and has completed the manufacturer training and proctoring in three patient administrations in SIR-spheres. Attached is a letter from Sirtex Medical attesting to his training and experience. His three supervised administrations were on February 28, 2019, June 5, 2019, and July 15, 2019. The Sirtex physician proctor was present for those cases and Dr. Thomas Fischback, M.D., who is an Authorized User for SIR-spheres on our license, served as Authorized User for those cases.

Also please remove the following Authorized Users from our license because they no longer practice at our facility:

John E. DePersio, M.D. Nazar Golewale, M.D. Gerard Duprat, Jr., M.D.

Thanks for your assistance with this license amendment request. If you have any questions or require additional information, please contact our Radiation Safety Officer, Daniel Archambeault at 574-647-7956 or by e-mail at <a href="mailto:darchambeault@beaconhealthsystem.org">darchambeault@beaconhealthsystem.org</a>.

Sincerely,

Diana Custer
Vice President, Operations

Diona Custr

Memorial Hospital



## SIRTEX MEDICAL INC.

300 Unicorn Park Drive Woburn, MA 01801 Tel: +1 (781) 721 3800 Fax: +1 (781) 721 3880

Ref: 105US03

June 5, 2019

Dr. Michael Hall Memorial Hospital 615 N. Michigan Street South Bend, IN 46601

Dear Dr. Hall;

Re: SIR-Spheres<sup>®</sup> Yttrium-90 Resin Microspheres Training, Evaluation, Certification (TEC) Program

I am writing to confirm that on February 22, 2019, Dr. Ramana Yedavalli presented and discussed the preparation of and procedures associated with SIR-Spheres yttrium-90 (Y-90) resin microspheres that are injected via the hepatic artery to treat patients with unresectable liver tumors. Dr. Ramana Yedavalli also proctored you for the administration of SIR-Spheres Y-90 resin microspheres.

Given your prior experience administering SIR-Spheres Y-90 resin microspheres at Memorial Hospital (2013-2014), I am pleased to inform you that Sirtex considers that you and your staff are trained in the preparation and clinical aspects of treating patients with SIR-Spheres Y-90 resin microspheres.

I would like to thank you and your team for your support and commitment to the Sirtex **Training**, **Evaluation**, **Certification** (TEC) Program.

Yours sincerely,

William T. Denman, MD Global Chief Medical Officer

Man I Davier, M.O.

cc: Steve Schilt, Regional Sales Manager TEC@sirtex.com

<sup>®</sup> SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

THU - 03 OCT AA STANDARD OVERNIGHT Fed 3x. 8149 7971 8199 60532 ∩L-\S ORD XH ENLA 00064 00300 Çŀ fedex.com 1800.GoFedEx 1.800.463.3339 60532-4352 **611**